NRAS and thyroid cancer, nonmedullary, 2: NRAS mutations were detected in 8.9% of the cases, being present in benign and malignant tumours, with a higher frequency in the FTA (35%—6 cases), 18% in CV-PTC (3 cases), 12% in FTC, FV-PTC and OV-PTC (2 cases each), and 6% in PDTC (1 case) and in the single distant metastasis analysed.